ADIL — Adial Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Adial Pharmaceuticals Announces Pricing Of $0.75 Million At-The-Market Registered Direct Offering
Brief: Adial Pharma Confirms Scheduling Of Meetings With FDA, European Regulatory Agencies Reg AD04
Brief: Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
Brief: Adial Pharmaceuticals Announces Positive In Vivo Data For Purnovate’S PNV-5030 As A Potential Treatment For Chronic Pain
Brief: Adial Pharmaceuticals Inc - On August 31, Received Written Notice From Nasdaq Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Adial Pharmaceuticals Names Cary Claiborne As Chief Executive Officer
Brief: Adial Pharmaceuticals Announces Topline Results For Onward Phase 3 Trial For Ad04 In Patients With Alcohol Use Disorder
Brief: Adial Pharmaceuticals Announces Database Lock For The Onward Phase 3 Clinical Trial
Brief: Adial Pharmaceuticals Awarded Additional U.S. Patent
Brief: Adial Pharmaceuticals Announces Research Collaboration With Medical College Of Wisconsin To Advance Purnovate's Adenosine Compounds As Potential Treatments For Diabetes And NASH
Brief: Adial Pharmaceuticals Provides Business Update And Reports First Quarter 2022 Financial Results
Brief: Adial Pharmaceuticals Announces Completion Of Last Patient, Last Visit In Its Phase 3 Trial Of Ad04
Brief: Adial Pharmaceuticals Receives Notice Of Allowance On U.S. Patent For Treatment For Opioid Use Disorder Using Ad04
Brief: Adial Announces Cary J. Claiborne Has Joined Company As Chief Operating Officer
Brief: Adial Pharmaceuticals Files For Resale Of Up To 200,000 Shares Of Common Stock By Selling Stockholder
Brief: Adial Pharmaceuticals Announces Positive Pre-Clinical Data For PNV2 As Drug Candidate For Triple Negative Breast Cancer
Brief: Adial Announces Positive Pre-Clinical Data For Purnovate's PNV-5030
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:48 AM
Brief: Adial Pharmaceuticals Says Over 50% Of Patients Complete Full 24-Week Treatment Period In ONWARD Phase 3 Trial Of AD04